450 related articles for article (PubMed ID: 31281107)
1. Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.
Venugopal S; Zhou S; El Jamal SM; Lane AA; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):545-554. PubMed ID: 31281107
[TBL] [Abstract][Full Text] [Related]
2. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U
Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088
[TBL] [Abstract][Full Text] [Related]
5. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
6. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
7. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Lee SS; McCue D; Pemmaraju N
Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
[TBL] [Abstract][Full Text] [Related]
8. Dendritic Cell Leukemia: a Review.
Tsagarakis NJ; Paterakis G
Curr Oncol Rep; 2020 May; 22(6):55. PubMed ID: 32415624
[TBL] [Abstract][Full Text] [Related]
9. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Alfayez M; Konopleva M; Pemmaraju N
Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
[No Abstract] [Full Text] [Related]
10. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
[TBL] [Abstract][Full Text] [Related]
11. Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies.
Laribi K; Denizon N; Besançon A; Farhi J; Lemaire P; Sandrini J; Truong C; Ghnaya H; Baugier de Materre A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1357-1367. PubMed ID: 27026248
[TBL] [Abstract][Full Text] [Related]
12. [Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].
Nguyen K; Korsing S; Mansour Y; Meier K
Dermatologie (Heidelb); 2023 Oct; 74(10):787-792. PubMed ID: 37407876
[TBL] [Abstract][Full Text] [Related]
13. Blastic Plasmacytoid Dendritic Cell Neoplasia: A Single Center Experience.
Demiröz AS; Demirkesen C; Salihoğlu A; Tüzüner N
Turk J Haematol; 2020 Feb; 37(1):48-52. PubMed ID: 31752482
[TBL] [Abstract][Full Text] [Related]
14. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A; Zhang Y; Sokol L
Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
[TBL] [Abstract][Full Text] [Related]
15. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
Cheng W; Yu TT; Tang AP; He Young K; Yu L
Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
[TBL] [Abstract][Full Text] [Related]
16. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract][Full Text] [Related]
17. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
18. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA
Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042
[TBL] [Abstract][Full Text] [Related]
19. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Beird HC; Khan M; Wang F; Alfayez M; Cai T; Zhao L; Khoury J; Futreal PA; Konopleva M; Pemmaraju N
Blood Cancer J; 2019 Dec; 9(12):99. PubMed ID: 31811114
[TBL] [Abstract][Full Text] [Related]
20. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.
Pagano L; Valentini CG; Grammatico S; Pulsoni A
Br J Haematol; 2016 Jul; 174(2):188-202. PubMed ID: 27264021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
